Silencing of endothelial CLIC4 or inhibition of Arf6 activity with Sec7 inhibitor H3 (SecinH3) prevent development of pulmonary hypertension in preclinical models of the disease. Here, ARF6 is linked to pulmonary arterial hypertension.